PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

  • Домашняя страница
    • О сайте
  • Материалы
    • Быстрые команды R Project
    • Ссылки
  • Инструменты
    • Рандомизационный список
  • Блог
    • Статистика
    • Phoenix WinNonlin
    • IT
    • Путевые заметки
  • Контакты
    • Контактные данные
    • Консультации
    • Конфиденциальность
  • Профиль
    • Войти
    • Зарегистрироваться

Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry – FDA

Опубликовано 3 октября, 201817 декабря, 2018 frozencat

Обновление руководства FDA:

Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry

Руководство замещает Adaptive Design Clinical Trials for Drugs and Biologics – 2010.

Рубрики: Блог

Навигация по записям

Предыдущая запись: Определение объема выборки для исследований биоэквивалентности с использованием компьютерного моделирования
Следующая запись: Работа с данными в IBM SPSS: присвоение меток переменным из другого источника

Свежие записи

  • Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
  • Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
  • Главные ошибки при формировании базы данных в MS Excel
  • Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
  • Julia:ReplicateBE – release 0.2.0

Галерея

20170730 121723
20180202 160114
IMG-20170806-WA0034
20180814 180918
20180128 180845
20180131 184314
  • Human medicines European public assessment report (EPAR): Datopotamab deruxtecan Daiichi Sankyo, datopotamab deruxtecan, Status: Application withdrawn
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-11
  • Human medicines European public assessment report (EPAR): Slenyto, melatonin, Date of authorisation: 20/09/2018, Revision: 14, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-11
  • Human medicines European public assessment report (EPAR): Uzpruvo, ustekinumab, Date of authorisation: 05/01/2024, Revision: 8, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-11
  • Human medicines European public assessment report (EPAR): Kaftrio, ivacaftor,tezacaftor,elexacaftor, Date of authorisation: 21/08/2020, Revision: 31, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-11
  • Taizhou Kangping Medical Science and Technology Co., Ltd. - 711081 - 10/09/2025
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-11 By FDA
  • Miers Laboratories, Ltd - 715378 - 11/03/2025
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-11 By FDA
  • IBSPOT.com Inc. - 715657 - 10/27/2025
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-11 By FDA
  • Human medicines European public assessment report (EPAR): Norvir, ritonavir, Date of authorisation: 25/08/1996, Revision: 71, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-11
  • Human medicines European public assessment report (EPAR): Bimervax, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 30/03/2023, Revision: 12, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-11
  • Human medicines European public assessment report (EPAR): Roctavian, valoctocogene roxaparvovec, Date of authorisation: 24/08/2022, Revision: 9, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-11
  • Human medicines European public assessment report (EPAR): mResvia, Respiratory syncytial virus mRNA vaccine (nucleoside modified), Date of authorisation: 22/08/2024, Revision: 7, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-11
  • Generic Drug Facilities, Sites and Organization Lists
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-10 By FDA
  • Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 38, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-10
  • Human medicines European public assessment report (EPAR): Verquvo, vericiguat, Date of authorisation: 16/07/2021, Revision: 1, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-11-10
  • Drug Alerts and Statements
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-11-10 By FDA
Предыдущие записи
Тема: Scaffold от Danny Cooper.